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Future unrelated medical costs need to be considered in cost 
effectiveness analysis 
New medical technologies that prolong life result in additional health care use in life years 
gained. Some of these costs in life years gained are considered to be related to the 
intervention while other costs are considered unrelated. Here, we argue that ignoring these 
so-called future medical costs in cost effectiveness analysis is contrary to common sense, 
results in lost health and fails to inform decision makers whom cost effectiveness is 
supposed to serve. 
Background 
Health services in most of the developed world are under increasing strain as populations 
age: this is no less true for being a cliché.1,2 An important driver of growing health care 
expenditures is the introduction of new medical technology (often targeted at the elderly).3 
Although some medical technology has made important contributions to improvements in 
population health, not all new technologies result in health gains at ಫacceptableಬ prices. Cost 
effectiveness analysis (CEA) aims to inform decision makers at what price new 
technologies yield health gains.  
The most notable and systematic use of CEA is in England, where the National Institute 
for Health and Clinical Excellence (NICE) has been established to assess whether new 
technologies within health care yield sufficient value for money to allow routine use within 
the English National Health Service (NHS). Consequently, NICE guidance with respect to 
the use of health care technologies but also their methodological guidance on how to assess 
health care technologies have been highly influential in England but also serve as role 
model for other countries wishing to use CEA results in decision making. When developing 
guidance, cost effectiveness is considered explicitly by NICE in the so-called assessment 
phase in which evidence on cost and effects is gathered, and subsequently in the appraisal 
phase in which there is a deliberation upon the gathered evidence.4 An intervention is 
GHHPHGFRVWHIIHFWLYHE\1,&(LIµits health benefits are greater than the opportunity costs 
of programmes displaced to fund the new technology, in the context of a fixed NHS budget. 
In other words, the general consequences for the wider group of patients in the NHS are 
considered alongside the effects for those patients who may directly benefit from the 
technology.¶4 In this article we question whether the current guidelines for health 
technology assessment used by NICE are appropriate given this definition of cost 
effectiveness. The point we want to take issue with in particular is the handling of 
³XQUHODWHGIXWXUHmedical FRVWV´ in cost-effectiveness analysis. These are now explicitly 
excluded from these analyses in current guidelines, but, as we will argue, they should be 
included to support better decisions.5   
Future costs and cost effectiveness analysis 
Medical interventions that increase life expectancy of patients may create additional 
consumption of medical goods and services in so-FDOOHGµDGGHGOLIH\HDUV¶$GGHG\HDUV
are those years that would not have been lived without the intervention. A part of this 
medical consumption in added years is directly related to the intervention. In case in of a 
successful heart transplantation costs of visiting the cardiologist in life years gained are 
considered related. These costs are typically included in economic analyses. Other costs in 
DGGHG\HDUVDUHQRWGLUHFWO\UHODWHGWRWKHLQWHUYHQWLRQDQGDUHWHUPHGFRVWVRIµXQUHODWHG
medical carH¶7KLVZRXOGIRULQVWDQFHEHWKHFDVHIRUcosts resulting of dementia care in 
added life years after the same heart transplantation. These costs are typically excluded 
from economic analyses. However, given the increased survival of older patients and a 
high concentration of spending in the elderly, it is likely that life prolonging technologies 
FUHDWHDORWRIµXQUHODWHG¶KHDOWKFDUHXVHLQOLIH\HDUVJDLQHGA recent study suggested that 
a substantial part of the rise in emergency admissions to hospitals can be explained by 
improved survival of patients from previous admissions, and therefore creation of a new 
set of frail patients, who would in previous years have died.6  
 
Whether we should worry about unrelated costs in added life years in cost-effectiveness 
analysis when we decide on a life prolonging technology is currently much debated.7,8 To 
better understand the relevance of unrelated medical costs when deciding on health care 
interventions we invite readers to consider the story in Box 1 where we present a stylized 
example relevant for individual decision making. If you, the reader, had to give advice to 
the family about this difficult choice, would you ignore the dialysis costs in informing their 
GHFLVLRQDERXWFKHPRWKHUDS\RQWKHJURXQGVWKDWWKH\DUH³XQUHODWHG´" 
 
Box 1: unrelated costs and individual decision making  
A 62 year old member of a family in a poor country without healthcare coverage has kidney 
failure and requires dialysis, imposing a significant but bearable recurrent financial burden 
on her family.  She then additionally receives an unrelated cancer diagnosis with a terminal 
prognosis.  The family can borrow money for chemotherapy ± their decision is whether to 
do so.  The financial costs of servicing the loan would be bearable in the absence of the 
dialysis costs, but together with the dialysis costs the family will be wiped out financially 
- the children will have to leave school and start work, the parents will have to work two 
jobs and can give up any hope of retirement, and even then they might be bankrupted and 
have to abandon the dialysis anyway.  The situation is tragic but a choice has to be made.  
 
While the example in Box 1 may highlight the salience of these costs, some authors have 
argued in favour of excluding future unrelated costs. Their main points are that these costs 
can be safely ignored as they are not material to decision making and including these costs 
would only complicate decision making and pose empirical challenges when one needs to 
estimate such costs.9,10 Other arguments against inclusion are that these costs relate to 
specific treatments that should be evaluated separately.10,11 However, research has called 
into question these arguments and develops theory which shows that including costs of 
unrelated diseases would increase population health in the long run.12 Furthermore, 
empirical problems in estimating such costs can largely be solved as there is ample research 
on the impact of ageing on health care use.  
 
It may seem counterintuitive that including more costs in an economic evaluation, thereby 
pushing the incremental cost effectiveness ratio (the ICER) upwards, ultimately results in 
more health. However, key to understanding this logic is that including future unrelated 
costs leads to different choices that on balance result in more health benefits. 12 Intuitively, 
including the costs of unrelated medical care makes sense as they also contribute to the 
health gains which are implicitly included in practice.5 By neglecting unrelated future 
costs, life-prolonging technologies appear to be more cost-effective than they truly are. 
Therefore, underestimating the costs of life prolonging health technologies might result in 
erroneously adopting life prolonging technology at the expense of interventions that yield 
more health per pound spent. Ultimately, future unrelated costs are real and will affect the 
budget left for other care. Given that NHS budgets are fixed opportunity costs of 
implementing new technologies consist of QALYs foregone due to disinvestment in 
technologies for unidentified patients. 13 Ignoring future unrelated medical costs results in 
an underestimate of QALY losses of unidentified patients in the future.  
 
Guidelines  
Whether or not unrelated costs are taken into account in economic evaluations in practice 
crucially depends on guidelines for economic evaluations. To ensure that economic 
evaluations are performed in a sound way, aligning with the goals and constraints of the 
NHS, they should be conducted by adhering to guidelines such as those developed by 
NICE.4 With respect to the inclusion of future costs current NICE guidelines for technology 
assessment advise that ³&RVWVUHODWHGWRWKHFRQGLWLRQRILQWHUHVWDQGLQFXUUHGLQDGGLWLRQDO
years of life gained as a result of treatment should be included in the reference-case 
analysis. Costs that are considered to be unrelated to the condition or technology of 
LQWHUHVW VKRXOG EH H[FOXGHG´ The Dutch Health Care Institute had identical advice 
regarding unrelated medical care as NICE, but recently recognized the inconsistency of 
ignoring these real costs and decided to change these guidelines to encourage inclusion of 
all future medical costs.14 Note that the Dutch are not the first to recommend inclusion of 
these costs as Swedish guidelines for cost effectiveness analyses have always 
recommended inclusion. Furthermore, recently updated guidance from the US panel on 
cost effectiveness also recommends inclusion of future unrelated medical costs.15 As a 
consequence of current NICE guidance, costs of dementia treatment in life years gained 
would be ignored in an economic evaluation of cancer treatment. The consequence is that 
the health losses as a result of disinvestment in old technologies might be greater than the 
health gains of investing in new technologies resulting in on balance health losses.  
Recent research has shown that value for money as measured by the incremental cost 
effectiveness ratio (ICERa) is an important determinant whether a technology will be 
recommended by NICE or not.16 On average, an increase of the ICER of e1,000 decreases 
the odds of being adopted by about 7%.16 Including future unrelated costs can have a big 
impact on the incremental cost effectiveness ratio (ICER). Although the numerical impact 
may differ from intervention to intervention, in general the impact of unrelated medical 
care will be bigger for life saving interventions targeted at elderly and frail people. While 
for interventions that do not extend life the ICER would be unaffected, including future 
unrelated medical costs could increase the ICER by thousands of pounds for interventions 
that extend life considerably but where life years gained are spent in poor health. Therefore, 
a change in NICE guidance could have a substantial impact on decisions. Box 2 gives an 
example which illustrates the impact of future unrelated costs for decisions reached by 
NICE. 
  
                                                 
a A central element of an economic evaluation is an Incremental Cost Effectiveness Ratio (ICER) which 
indicates how much has to be paid for an additional QALY by adopting a new intervention relative to some 
relevant comparator (e.g. current care). In the UK, the ICER is a ratio that is derived by dividing the 
additional costs falling, roughly speaking, on the NHS and also the Personal Social Services (PSS) budget 
by the additional population  health gains measured in terms of Quality Adjusted Life Years (QALYs). 
Box 2: future unrelated medical costs and the cost effectiveness of transcatheter aortic 
valve implantation (TAVI) 
Transcatheter aortic valve implantation (TAVI) is a recent developed technology that 
prolongs life for patients with severe aortic stenosis and coexisting conditions which are 
not candidates for surgical replacement of the aortic valve.17 Recently, an economic 
evaluation of TAVI was produced using NICE guidance which led to a base case ICER 
estimate of 16,100 pound per QALY and a health gain per patient of 1.56 QALYs.17 In line 
with NICE guidelines, costs of reoperation were included, but future unrelated costs in life 
years gained, such as costs of treating dementia, were excluded.  In case of TAVI, eligible 
patients are old (>75), face a high mortality risk and generally have multiple 
comorbidities.17 Health care consumption for other diseases besides heart disease in 
additional life years of this group of patients can therefore expected to be relevant. If we 
were to include future unrelated costs the ICER would increase from £16,100 to £ 23,500 
per QALY gained.12 With a threshold of £20,000, in- or exclusion of future unrelated 
medical costs could mean the difference between adopting and rejecting a technology. 
However, if TAVI would be adopted based on the ICER of £16,100 this results in health 
losses if the technology that is displaced has a cost effectiveness of £20,000 per QALY 
gained. More specifically, as the total costs for the TAVI procedure for one patient 
(including future unrelated medical costs) are about £37,000.- one could have gotten 1.85 
QALY (37,000/20,000) rather than the 1.56 produced by the TAVI technology. As there 
are about 2,000 patients eligible for TAVI in England this would result in a health loss of 
almost 700 QALYs.  
 
Ethical considerations 
Could the analysis which we present above have ethically undesirable implications?  It is 
possible to construct examples where including unrelated future costs in analysis can 
produce conclusions which are hard to swallow ± for example when considering life 
extending interventions in institutionalised and/or chronically ill patients (see Box 3).  
  
Box 3: future costs and ethical issues  
Life extending treatments in patients with chronic kidney disease (CKD) on dialysis are 
examples of treatments in which the in- or exclusion of future unrelated medical costs can 
have a very large impact on the ICER.19 For such patient groups future unrelated medical 
costs include the costs of dialysis in life years gained. These costs of dialysis are typically 
extremely high, and dialysis may in fact be considered cost-ineffective if judged against 
conventional thresholds. However, without ongoing dialysis, patients with end-stage renal 
disease face certain death. As the ICER of dialysis is already very high, the inclusion of 
dialysis costs in CEAs of interventions that extend the lives of dialysis patients, will lead 
to a situation in which even the most effective life-extending intervention will turn out to 
be cost-ineffective. For instance, statin treatment which is very cost effective in some 
patient groups, may be deemed to be cost-ineffective in CKD patients on dialysis. It is clear 
that this raises questions regarding the ethical implications of including costs in gained life 
years which will have to be dealt with in priority setting in health care. In response to this, 
some authors have actually argued that including the costs of dialysis when evaluating 
VWDWLQV ZRXOG EH µXQHWKLFDO¶ DQG WKHUHIRUH SOHDG IRU LJQRULQJ WKHVH FRVWV LQ OLIH \HDUV 
gained.19 However, as statin treatment in this patient group increases the need for dialysis, 
ignoring these costs implies ignoring real (and potentially large) opportunity costs in terms 
of health forgone within the health care sector.  
 
We share the moral intuition that denying access to life-extending treatments to dialysis 
patients specifically, is ethically challenging. One prominent reason for this is that patients 
with chronic kidney disease are already, through their illness, disadvantaged relative to the 
general population and so might deserve exceptional consideration.  Another reason is that 
denying a treatment for a specific minority subpopulation, when that treatment is available 
to everyone else, might be socially divisive and contrary to the concept of universal 
coverage.   
One might argue that denying any individual a therapy that offers them benefits because of 
costs is ethically troubling. Yet this is the reality of opportunity costs in the context of 
budget constraints. The concept of opportunity cost is not only an economic concept but 
also an ethical one, as the opportunity costs consist of health losses in other patients. 
Pretending such costs do not exist, does not seem to us to be ethically acceptable.   
Conclusion 
The coming pressures on the healthcare system from our ageing population will be intense.  
It is more important than ever that decisions about resource allocation are made in a spirit 
of stewardship, informed by robust common sense.  We argue that current technical 
guidance on unrelated future costs in many countries does not meet this standard, and that 
NICE should set an example and follow the Dutch change in guidelines and recommend 
inclusion of future unrelated medical costs in health technology assessments. For some 
patient groups including future unrelated medical costs may imply a huge increase in the 
ICER for life prolonging technologies and thereby trigger difficult ethical debates. 
However, NICE stresses that decisions should be made in a way which is procedurally fair, 
which allows for such arguments to be raised and deliberated upon when appraising the 
evidence.20 The task of the analyst in these situations is to provide decision makers with a 
full picture of the relevant consequences for the healthcare budget now and in the future. 
Expert advisers ದ whether to a family or to a nation ದ  have the responsibility to present all 
relevant information to those whom society has seen fit to entrust with decision making 
responsibility.  
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